GlassScriptPhysician profile
William J Jagust
NPI 1265765622
$71,112.88
in general payments reported to CMS, 2019-2025
6 companies · $1,650 in 2025
The $1,650 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,475 · 2020: $16K · 2021: $5,328 · 2022: $11K · 2023: $13K · 2024: $15K · 2025: $1,650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $30K · Food and Beverage: $70.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,757.50 |
| Food and Beverage | $70.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $33,242.50 | 2019-2024 | |
| Eli Lilly and Company | $25,850.00 | 2022-2025 | |
| Eisai INC. | $7,200.00 | 2022-2023 | |
| Grifols Shared Services North America, INC. | $4,750.00 | 2019 | |
| Ge Healthcare | $70.38 | 2024 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Jagust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.